BriaCell Therapeutics Corp. (BCTX)

Market Cap	14.35M
Revenue (ttm)	n/a
Net Income (ttm)	-19.43M
Shares Out	1.76M
EPS (ttm)	-83.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	132,032
Open	8.25
Previous Close	8.21
Day's Range	8.11 - 9.33
52-Week Range	6.00 - 214.50
Beta	1.47
Analysts	Strong Buy
Price Target	40.00 (+359.77%)
Earnings Date	Oct 28, 2025

About BCTX

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. I...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: BCTX
• Website: https://briacell.com

Analyst Summary

According to one analyst, the rating for BCTX stock is "Strong Buy" and the 12-month stock price target is $40.0.

Price Target

$40.0

(359.77% upside)

Analyst Consensus: Strong Buy